/TVGN
TVGN Stock - Tevogen Bio Holdings Inc.
Healthcare|BiotechnologyNASDAQ
$0.38-0.26%
$0.00 (-0.26%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.42
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TVGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.38 – $0.38
TARGET (TP)$0.44
STOP LOSS$0.35
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.81
52W High$1.92
52W Low$0.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | $-403,581 | $-378,357 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-53,564,488 | $-8,843,025 | $-953,083 | $-4,618,462 |
| Net Income | $-10,114,380 | $-60,477,680 | $4.41M | $-15,596,798 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-0.09 | $-0.00 | $0.04 | $-0.33 |
Company Overview
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 2533.7% Upside
Now
$10
Low
$10
Average
$10
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 4th 2025 | D. Boral Capital | Initiation | Buy | $10 |
Earnings History & Surprises
TVGNBeat Rate
50%
Last 4 quarters
Avg Surprise
+0.7%
EPS vs Estimate
Beats / Misses
2/2
Last 12 quarters
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
-56.1%
$-0.05vs$-0.03
Q2 25
-31.9%
$-0.06vs$-0.05
Q3 25
+40.0%
$-0.03vs$-0.05
Q4 25
+50.7%
$-0.03vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.06 | $-0.03 | +50.7% | ✓ BEAT |
Q3 2025 | Aug 19, 2025 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.05 | $-0.06 | -31.9% | ✗ MISS |
Q2 2025 | Apr 2, 2025 | $-0.03 | $-0.05 | -56.1% | ✗ MISS |
Q4 2024 | Nov 19, 2024 | — | $-0.03 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.06 | — | — |
Q2 2024 | May 27, 2024 | — | $0.08 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.01 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.16 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.26 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.05 | — | — |
Q3 2022 | Sep 29, 2022 | — | $0.03 | — | — |
Q2 2022 | Jun 29, 2022 | — | $0.00 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 29, 2021 | — | $0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Latest News
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5
➖ NeutralBenzinga•Nov 20, 2025, 01:13 PM
Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibility
📈 PositiveBenzinga•Nov 5, 2025, 08:22 PM
Tevogen Clarifies GAAP-Reported Deficit, Plans Non-GAAP Metrics Disclosure Post Q3 2025 Filing
➖ NeutralBenzinga•Nov 3, 2025, 07:55 PM
Tevogen Intends To Collaborate With Government Initiatives, Long COVID Patient Organizations, And Major Healthcare Providers To Expedite Development Of TVGN 489; Establishes A Dedicated Communication Channel For Long COVID Updates At longCOVID@tevogen.com
📈 PositiveBenzinga•Oct 15, 2025, 07:52 PM
Tevogen Bio Announces Progress On Its PredicTcell Platform Which Uses Advanced Machine Learning And Transformer-Based Models To Accelerate Precision Immunotherapy Development
📈 PositiveBenzinga•Sep 25, 2025, 12:37 PM
Tevogen Highlights Potential Of Precision T Cell Therapy TVGN 489 To Target Persistent Viral Reservoirs In Long COVID Treatment
📈 PositiveBenzinga•Sep 23, 2025, 12:44 PM
Tevogen Bio Estimates TVGN 116 Cumulative 5-Yr Top-Line Revenue To Be ~$6.5B; Risk Adjusted Net Present Value For TVGN 116 Is Estimated To Exceed ~$325M In US Alone
📈 PositiveBenzinga•Sep 9, 2025, 07:20 PM
Tevogen Values TVGN-489 T Cell Therapy For COVID-19 And Long-COVID At $9B-$11B
📈 PositiveBenzinga•Sep 8, 2025, 01:32 PM
Tevogen Projects $3.5B Revenue For EBV-Targeting Therapy TVGN 930, With rNPV Exceeding $250M In U.S. Rare Disease Market
📈 PositiveBenzinga•Sep 4, 2025, 07:54 PM
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 4, 2025, 11:11 AM
Tevogen Highlights Clinical Data For TVGN 489, A T Cell Therapy Targeting COVID-19 In Immunocompromised Patients
📈 PositiveBenzinga•Sep 3, 2025, 08:17 PM
Tevogen Reports 24% Rise In Institutional Ownership In Q2 2025, Led By Morgan Stanley And BlackRock
📈 PositiveBenzinga•Aug 25, 2025, 07:13 PM•Also:
Tevogen Bio Secures Up To $50M In Financing Following $94.9M Liability Elimination; Formalizes Agreement First Announced May 2024
📈 PositiveBenzinga•Aug 19, 2025, 07:45 PM
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 11:33 AM
Tevogen shares skyrocket as it projects $1B in revenue for its oncology pipeline
📈 PositiveSeeking Alpha•Apr 28, 2025, 08:51 PM
Frequently Asked Questions about TVGN
What is TVGN's current stock price?
Tevogen Bio Holdings Inc. (TVGN) is currently trading at $0.38 per share. The stock has moved -0.26% today.
What is the analyst price target for TVGN?
No analyst price targets are currently available for this stock.
What sector is Tevogen Bio Holdings Inc. in?
Tevogen Bio Holdings Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TVGN's market cap?
Tevogen Bio Holdings Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does TVGN pay dividends?
No, Tevogen Bio Holdings Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
CLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
GLSI
Greenwich LifeSciences, Inc.
$13.01
Mkt Cap: $0.2B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
ONCY
Oncolytics Biotech Inc.
$1.01
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TIL
Instil Bio, Inc.
$11.27
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
Explore stocks similar to TVGN for comparison